Boston University · PharmacologyThe NeuroVasodilator Lab
Weiming Xia · Boston, Massachusetts
Research Focus
Dr. Weiming Xia's lab at Boston University focuses on finding new treatments for Alzheimer's disease (AD) by analyzing large datasets from veterans' health records. The lab investigates how certain medications, particularly vasodilators, may slow the progression of AD and alleviate cognitive impairments. By combining big data analysis with experiments in mouse models, the lab aims to uncover potential therapies that can be quickly developed for patients.
Alzheimer's Diseasebig datavasodilatorscognitive impairmentmouse modelsneurodegenerationhealth recordsdrug discoveryproteomicsRNA sequencing
Research Aims
5AIM 01Analyze veterans' health records to identify medications that delay the onset of Alzheimer's disease.
AIM 02Test the effects of vasodilators like Belumosudil on cognitive impairment in Alzheimer's mouse models.
AIM 03Examine molecular mechanisms of vasodilators using single nucleus RNA sequencing and proteomics.
AIM 04Develop fast-tracked therapies for Alzheimer's disease from identified medications.
AIM 05Assess the clinical effectiveness of identified medications against benchmarks.
Skills the Lab Values
data miningEHR analysismouse modelsprotein analysismolecular profilingRNA sequencingstatistical analysisdrug pharmacologybehavioral assayscell culture
Output against the department
Publications268top 30% of dept.137th of 462
this lab
most publishedleast published
Citations17ktop 22% of dept.103rd of 462
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.